S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative breast
cancer that has spread to other places in the body. Using markers to prompt when scans should
be ordered may be as good as the usual approach to monitoring disease.

Intervention

Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration

Condition

Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29

Investigators

Melissa Accordino, Gary E. Goodman, Christopher M. Reynolds, Victor G. Vogel, Bryan A. Faller, Howard M. Gross, Luis Baez-Diaz, Jeffrey K. Giguere, Pratima Chalasani, Augusto C. Ochoa, Hanh P. Mai, Douglas J. Weckstein, Emily G. Robinson, Timothy D. Moore, Rex B. Mowat, Serge Dauphin, Mehmet F. Hepgur, Dany El-Sayah, Melissa K. Accordino, Kathleen J. Yost, Richard L. Deming, Della F. Makower, Jeffrey L. Berenberg, Sima Ehsani, Drew S. Dill, Jay W. Carlson, Sarah S. Mougalian, Shalini Mulaparthi, Shaker R. Dakhil, Debra M. Prow, Maitri Kalra, Brian R. Murphy, Eric Bravin, Paul M. Barr, Gary V. Burton, Ana Maria Lopez, Corrine L. Zarwan, Thomas J. Summers, Ursa A. Brown-Glaberman, Nicholas DiBella, Lara N. Durna, John M. Schallenkamp, Mukund Nadipuram, Gary C. Doolittle, Mehmood H. Hashmi, Matthew L. Ryan, David M. King, Samer S. Kasbari, Janelle M. Meyer, Mohammed Saad, Demet Gokalp Yasar, Preston D. Steen, Michael A. Finan, Eric Y. Chen, Christopher B. Jones, John A. Pablo, Bonni L. Guerin

See list of participating sites